The EAHP Board, elected for three-year terms, oversees the association’s activities. Comprising directors responsible for core functions, it meets regularly to implement strategic goals. Supported by EAHP staff, the Board controls finances, coordinates congress organization, and ensures compliance with statutes and codes of conduct.
Affiliation
The Royal Marsden NHS Foundation Trust
Country
United Kingdom
Current Status, Position
Mr Richard Nuttall is the Lead Electronic Chemotherapy Prescribing Pharmacist at the Royal Marsden Hospital in London. He is also the national lead for dose banding chemotherapy for NHS England.
Education
Mr Nuttall studied pharmacy at the Central Institute of Technology in Wellington (NZ) and completed the Certificate in Pharmacy Practice and the Paediatric Practice Module from the School of Pharmacy in London. He also completed the Mary Seacole Leadership programme from the NHS England Leadership Academy.
Research Area
Mr Nuttall helped develop the Royal Marsden Hospital’s electronic chemotherapy prescribing system and works closely with the clinical trials team and specialist haemato-oncology pharmacists to develop chemotherapy protocols. He led the development of a system for dose banding chemotherapy that has been adopted across NHS England and now leads the team responsible for maintaining this.
Conflict of interest: none